Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
Become a Member | Sign in
Home>News>This Article

VolitionRx Announces Collaboration with Wales Cancer Bank

Published: Thursday, January 10, 2013
Last Updated: Thursday, January 10, 2013
Bookmark and Share
VolitionRx Limited announces that it will commence a large internal clinical study for its Nucleosomics® diagnostic products this month.

This trial is being undertaken in addition to its four ongoing external clinical trials. The trial will be carried out in Volition’s laboratory on patient blood samples supplied by the Wales Cancer Bank (, which is based in Cardiff, in the United Kingdom.

Beginning late January, NuQ® tests will be conducted on blood samples taken from more than 800 cancer patients by the Wales Cancer Bank as well as healthy control volunteers. The expected sample distribution is as follows:

• Breast cancer: approx. 550 patients with a variety of subtypes, including invasive ductal carcinoma, invasive lobular and tubular carcinomas, and in-situ carcinoma ductal
• Colorectal cancer: approx. 230 patients with a variety of subtypes, at various stages from Stage A to Stage D
• Plus smaller numbers of patients with lung and pancreatic cancers.

The study follows a highly successful pilot study on 100 patient samples from the Wales Cancer Bank, (results of which were announced in December 2012), after which Volition was awarded scientific approval from the Bank for the number of patients needed for a full scale clinical trial.

Jake Micallef, Chief Scientific Officer of VolitionRx, says: “These larger studies follow successful completion of our own internal pilot studies. This is the next step in obtaining European market approval for Nucleosomics diagnostic tests (beginning with the patient numbers needed for breast and colorectal cancer), and establishing them in routine clinical use.”

Professor Malcolm Mason, Director of the Wales Cancer Biobank, says: “We are delighted to be providing patient blood samples for Volition’s cancer trial. Their technology shows promise and we were very happy with their initial results in the pilot study carried out in 2012. We look forward to seeing the results from this larger trial.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

VolitionRx Invests in Laboratory Automation System
Automation will accelerate analysis of blood samples for expanded colorectal cancer screening trial.
Wednesday, August 13, 2014
Scientific News
HIV Patients Should Be Included in Early Clinical Trials of Anti-TB Drugs
Tuberculosis is the number one cause of death in HIV-infected patients in Africa and a leading cause of death in this population worldwide.
Multi-Gene Test Enables Some Breast Cancer Patients to Safely Avoid Chemotherapy
A major study is providing the best evidence to date that a 21-gene test done on the tumor can identify breast cancer patients who can safely avoid chemotherapy.
Low Dose Beta-Blockers As Effective As High Dose After a Heart Attack?
Heart attack patients live as long – or even longer – on one-quarter the suggested dose.
Antidepressants Plus Blood-Thinners Slow Down Brain Cancer
EPFL scientists have found that combining antidepressants with anticoagulants slows down brain tumors (gliomas) in mice.
Old Drug Performs New Tricks
Cambridge-led research reveals the powers of a "wonder drug" that has lain under the noses of doctors for 50 years.
Electronic Reminders Keep TB Patients on Track With Medication In China
Giving electronic reminders to tuberculosis (TB) patients in China can reduce the amount of medication doses they miss by half, according to new research.
Common Drug Presents Fracture Risk To Older Women
Researchers are urging caution in prescribing one of the world’s most commonly issued drug groups, citing links to increased fracture risks in older Australian women.
Combining Epigenetic Therapies and Immunotherapies Improves Cancer Outcomes
Recent data suggest that epigenetic therapies are likely to provide additional clinical benefit to cancer patients when rationally combined with immunotherapeutic drugs.
LiMAx Test Shows Reversibility of Fatty Liver Disease After Obesity Surgery
Clinical study provides evidence for functional liver recovery after weight loss.
Landmark NIH Study Shows Intensive Blood Pressure Management May Save Lives
Lower blood pressure target greatly reduces cardiovascular complications and deaths in older adults.
Scroll Up
Scroll Down

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos